Search Results
AG 555 10 mg | 100.00%
TargetMol
MTX-211 5 mg | 100.00%
TargetMol
MTX-211, an inhibitor of EGFR and PI3K, is used for the therapy of cancer and other diseases.
More Information Supplier PageSB756050 5 mg | 98.35%
TargetMol
JK-P3 25 mg | 99.50%
TargetMol
JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50: 7.8 μM). JK-P3 inhibits FGFR 1/3 kinase activity in vitro, but has no effect on FGFR signaling in cell-based assays. The compound blocks wound healing and tube formation in HUVEC without effecting endothelial cell proliferation.
More Information Supplier PageBatimastat 10 mg | 98.55%
TargetMol
Batimastat (BB-94) is an effective, broad-spectrum matrix metalloprotease (MMP) inhibitor. Batimastat induces extracellular matrix degradation and inhibits angiogenesis, tumor growth and invasion, and metastasis.
More Information Supplier PageML-18 5 mg | 100.00%
TargetMol
ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC50 of 4.8 μM.
More Information Supplier PageML-18 50 mg | 100.00%
TargetMol
ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC50 of 4.8 μM.
More Information Supplier PageML-18 25 mg | 100.00%
TargetMol
ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC50 of 4.8 μM.
More Information Supplier PageML-18 10 mg | 100.00%
TargetMol
ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC50 of 4.8 μM.
More Information Supplier Page
